HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone...
Industry veteran Mike Heaton takes the helm to accelerate innovation and further enhance DASI, LLC's market position
MIAMI, Jan. 13, 2025 /PRNewswire/ -- DASI, LLC,...
New Release Windows for Mobile Version Announced
Los Angeles, Jan. 13, 2025 /PRNewswire/ -- Today, Delta Force developer Team Jade revealed their plans for continuing...
PANAMA CITY, Jan. 13, 2025 /PRNewswire/ -- BingX, a global leading cryptocurrency exchange, has announced the launch of SOLV token from Solv Protocol on BingX...
SINGAPORE, Jan. 13, 2025 /PRNewswire/ -- Luzerne Pte Ltd is proud to announce its crucial role in helping the Dehua Ceramic Trade Association (China)...
HONG KONG, Jan. 13, 2025 /PRNewswire/ -- Gianna Lullume, an innovative brand committed to improving infant sleep and promoting family well-being, is proud to...
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc....